The CD4 receptor is the primary entry receptor for the human immunodeficiency virus.
Introduction
The cluster of differentiation 4 (CD4) receptor is a 55 kDa type I integral membrane protein consisting of four In lymphocytic cells, the lymphocyte C-terminal Src kinase (Lck) is noncovalently linked to the CD4 receptor by interacting with two closely spaced cysteine residues in the cytoplasmic tail of CD4 [6] . Next to its signaling function in T cell activation, Lck inhibits endocytosis of the CD4 receptor by preventing the entry of CD4 into clathrin-coated pits [7] . The CD4 receptor is constitutively internalized and recycled in nonlymphoid cells, but is excluded from the endocytic pathway in lymphocytic cells [8] . Lck also targets the CD4 receptor to specialized lipid microdomains preferentially localized on microvilli, which are important in antigen recognition [9, 10] . The CD4 receptor is also known as the primary entry receptor for HIV. Binding of a glycoprotein gp120 trimer on the surface of HIV to three CD4 receptors on the target cell induces conformational changes in gp120 that enables interaction with co-receptors [23, 24] . Coreceptor binding induces conformational changes in the transmembrane glycoprotein gp41, mediating fusion of the viral membrane with the target cell membrane [25] . 
The CD4 receptor in T cell activation
During activation of T cells, the CD4 receptor can fulfill several roles including an adhesion function, a signaling function as well as enhancement of T cell sensitivity to antigens.
Adhesion function of the CD4 receptor
The CD4 receptor was shown to exert an intercellular adhesion function during T cell activation and was therefore described as a co-receptor [28] . The CD4 receptor stabilizes the interaction between the TCR on CD4 can interact with the α2 or β2 domain of MHC class II, thereby stabilizing the interaction between the TCR on the T cell and the MHC class II molecule on the antigen-presenting cell.
The CD4 receptor as signaling molecule
More important than its function in intercellular This is an important immunoregulatory mechanism to maintain homeostasis and prevent tissue damage. The binding of TCR1 to an agonist peptide-MHC molecule creates a hotspot for activation that can recruit TCR2 via the CD4 receptor associated with it. TCR2 is then able to bind to an endogenous peptide-MHC molecule and the resulting stable pseudodimer complex, as shown on the right side of the figure, activates intracellular T cell signaling starting with the Lck kinase of the recruited CD4 receptor. The CD4 receptor thus enables the use of endogenous peptide-MHC molecules to achieve maximal sensitivity of T cells.
The CD4 receptor in T helper cell differentiation and T cell chemotaxis
Besides its role in T cell activation, the CD4 receptor is suggested to be involved in peripheral T cell differentiation towards the Th2 subset. When CD4 + T cells were activated in vitro in the presence of a nondepleting anti-CD4 monoclonal antibody, a Th2type response was induced with elevated levels of IL-4
and IL-13 [58] . Additionally, development of the Th2 subset was impaired in CD4 -/mice [59, 60] . CD4dependent signaling pathways would be involved in the regulation of a late checkpoint in the expansion and commitment phase of Th2 development, which is associated with resistance to activation-induced cell death [61] . Lck in turn would mediate Th2 differentiation through effects on the Th1 transcription factor T-bet and on the Th2 transcription factor GATA3 [62] .
Furthermore, CD4 was identified as the primary receptor for the pro-inflammatory cytokine IL-16 that is implicated in the pathogenesis of asthma and several autoimmune diseases by recruitment of CD4 + T cells to sites of inflammation [63] . IL-16 inhibits HIV-1 and SIV infection, as well as T cell activation in the mixed lymphocyte reaction and after stimulation with anti-CD3 antibodies [64, 65] 
Interference with CD4 receptor function
The important role of the CD4 receptor in the immune system is demonstrated by the immunosuppressive potential of anti-CD4 monoclonal antibodies. The small molecule CADA down-modulates the CD4 receptor and may therefore also have immunosuppressive effects.
Anti-CD4 monoclonal antibodies

Depleting anti-CD4 monoclonal antibodies
The depleting anti-mouse CD4 monoclonal antibody GK1.5 and the depleting anti-rat CD4 monoclonal antibody OX38 were successfully used in rodent skin and small bowel allograft transplantation models [74, 75] . Several other depleting anti-CD4 monoclonal antibodies showed benefit in transplantation models with various organs. CD4 + T cells are depleted by these antibodies by antibody-dependent cellular cytotoxicity or by complement-dependent cytotoxicity [76] . Massive transgenic or transduced allografts were performed [77, 78] . Still, these depleting anti-CD4 monoclonal antibodies, while being immunosuppressive, have been found to deplete Treg cells too and thereby inhibit the induction of antigen tolerance [79] .
Nondepleting anti-CD4 monoclonal antibodies
The immunosuppressive potential of depleting anti-CD4 monoclonal antibodies is obvious, but it was also shown that nondepleting anti-CD4 monoclonal antibodies could induce a permanent state of antigen-specific unresponsiveness (tolerance) in mice [80] . Nondepleting anti-CD4 monoclonal antibodies were able to control collagen-induced arthritis and experimental autoimmune encephalomyelitis in mice [81, 82] . These antibodies often did not only prevent, but also control ongoing autoimmune diseases. The effect of nondepleting anti-CD4 monoclonal antibodies was not restricted to rodent models, as it was shown in baboons that the humanized nondepleting anti-CD4 monoclonal antibody TRX1 is able to induce antigen-specific tolerance without longterm immunosuppression [83] .
These nondepleting anti-CD4 monoclonal antibodies may have several mechanisms of action. Using in vitro T cell activation assays, no correlation was found between the degree of T cell activation inhibition and the specificity of the monoclonal antibodies for different regions on the CD4 receptor, even not the binding site of MHC class II [84] . CD4 down-modulation may be required for the tolerizing effect of nondepleting anti-CD4 monoclonal antibodies and it was shown in vitro that resting CD4 + T cells absolutely require Fc receptormediated crosslinking of a humanized nondepleting anti-CD4 antibody for CD4 to be down-modulated, while activated CD4 + T cells did not [85, 86] .
In a collagen-induced arthritis model in mice, the nondepleting anti-CD4 antibody KT6 seemed to control pathogenic CD4 + T cells by switching their cytokine production from a Th1-to a Th2-like profile [81] .
Additionally, production of the Th1 cytokine interferonγ was severely reduced by the nondepleting anti-CD4 antibody RIB5/2 after allograft transplantation in rats [87] . An in vitro study with the nondepleting anti-mouse CD4 antibody YTS177.9 showed that IL-2 secretion was suppressed by this antibody through inhibition of the transcription factors NFAT and activator protein-1 (AP-1) [88] .
Another mechanism that was proposed to explain the of the responding CD4 + T cells in vitro [95] . The signaling profile of these anti-CD4-treated cells resembles that of anergic cells. Additionally, in the above-mentioned Foxp3 mutant scurfy mice, tolerance induction by YTS177.9 was associated with downregulation of the co-stimulatory tumor necrosis factorreceptor superfamily members OX40 and CD30 [92] .
Signaling through OX40 and CD30 promotes the differentiation and survival of CD4 + T cells that initiate autoimmunity in scurfy mice [96] . OX40 is also implicated in other autoimmune conditions, such as rheumatoid arthritis and multiple sclerosis [97] . 
Cyclotriazadisulfonamide (CADA)
The small molecule CADA is a synthetic macrocycle that was selected from an antiviral HIV screening program of the US National Cancer Institute (Figure 4 ).
CADA was shown to have a broad antiviral activity against different HIV strains in several T cell lines and in peripheral blood mononuclear cells [100, 101] . This antiviral effect of CADA is due to specific downmodulation of the CD4 receptor, which is the primary entry receptor for HIV. For 19 CADA analogs, it was shown that the CD4 down-modulating activity directly correlates with their anti-HIV potency [102] . by selectively binding to its signal peptide [103] . In contrast, no interaction of CADA with the murine CD4 signal peptide was observed. CADA was therefore identified as the first signal peptide-binding compound that selectively inhibits the translocation of a specific protein into the endoplasmic reticulum in a signal peptide-dependent way. The immunosuppressive potential of CADA is currently under investigation. Due to its unique mechanism of CD4 receptor downmodulation, CADA may provide a fascinating example of CD4-involved immunosuppression.
Conclusion
The CD4 receptor plays a crucial role in 
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